Medicare AdvantageDocumentationMedium impact
MA08.065k, Octreotide Acetate (Sandostatin® LAR Depot)
Independence Blue Cross·Endocrinology, Gastroenterology, Oncology·Pharmacy
Effective date
Aug 18, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated the medical necessity criteria and medical coding requirements for Octreotide Acetate (Sandostatin LAR Depot), a specialty pharmacy medication used primarily for treating certain endocrine tumors and gastrointestinal conditions. This change affects how providers must document medical necessity and potentially changes billing codes for this high-cost injectable medication.
Action Required
By August 18, 2025: Billing team and providers must review updated medical necessity criteria for Octreotide Acetate prescriptions. Update documentation templates to ensure compliance with new medical necessity requirements. Verify any coding changes in billing system. Claims may be denied if new medical necessity criteria are not met.